LINGAIN

OFFICIAL TITLE: PROSPECTIVE EVALUATION OF PREDICTIVE/PROGNOSTIC IMMUNOGENICITY BIOMARKERS FOR TARGET THERAPY IN HER2-POSITIVE EARLY BREAST CANCER WITHIN THE PHERGAIN CLINICAL STUDY.

PROJECT DETAILS

THE LINGAIN PROJECT, AS A SUBSTUDY OF THE PHERGAIN TRIAL, HAS THE POTENTIAL INTEREST TO IDENTIFY IMMUNOGENICITY BIOMARKERS OF RESPONSE OR RESISTANCE LINKED TO TARGETED ANTI-HER2 THERAPY. IN THIS EXPLORATORY AND COMPREHENSIVE STUDY, WE HYPOTHESIZE THAT THE ACTIVATION OF THE DIFFERENT SUBTYPES OF ΓΔ T CELLS IN PERIPHERAL BLOOD DURING DUAL HER2 BLOCKADE WITH TRASTUZUMAB AND PERTUZUMAB IS A SIGNAL OF IMMUNE RESPONSE, AND IT COULD BE CONSIDERED AN EARLY MARKER USEFUL TO PREDICT THE EFFICACY OF BIOLOGICAL THERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

HER2+ EBC

Sub-study

42

10

Spain

Recruitment closed